Dr. Julie Lemieux is a hemato-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Lemieux is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.
Dr. Lemieux is a member of the Canadian Clinical Trial Group for quality of life in breast cancer. She is also a scientific committee member for the McPeak-Sirois research group.
Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and monitoring of cancers and benign breast diseases.
Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.
Support the quality of life
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.
1050, chemin Sainte-Foy
Canada G1S 4L8
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical TrialJournal Article
JAMA, 327 (20), 2022.
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the linesJournal Article
Ther Adv Med Oncol, 14 , 2022.
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysisJournal Article
Eur J Cancer, 152 , 2021.
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32Journal Article
J Natl Cancer Inst, 113 (2), 2021.
Association of Breast Tumour Expression of Cannabinoid Receptors CBR1 and CBR2 with Prognostic Factors and Survival in Breast Cancer PatientsJournal Article
J Pers Med, 11 (9), 2021.
Identifying Clinicopathological Factors Associated with Oncotype DX 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, CanadaJournal Article
J Pers Med, 11 (9), 2021.
Stress-buffering effect of social support on immunity and infectious risk during chemotherapy for breast cancerJournal Article
Brain Behav Immun Health, 10 , 2021.
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs PlaceboJournal Article
JNCI Cancer Spectr, 5 (5), 2021.
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trialJournal Article
NPJ Breast Cancer, 7 (1), 2021.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyJournal Article
Lancet Oncol, 22 (2), 2021.
- Age-related patterns in the experience of chemotherapy-induced peripheral neuropathy, from 2019-10-01 to 2024-09-30
- Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, from 2021-12-01 to 2023-09-30
- NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25
- PALbociclib CoLlaborative Adjuvant Study (PALLAS study), from 2017-05-17 to 2025-12-25
- Perfectionism and psychosocial adjustment to cancer : A mixed methods study, from 2020-03-31 to 2024-03-31
- Projet pilote de l'utilisation d'une application pour le suivi et la prise en charge des effets secondaires associés aux traitements anti-néoplasiques oraux chez les patientes avec cancer du sein, from 2021-08-01 to 2023-07-31
- Une infrastructure IA multi-usagers clé en main pour gérer le cycle de vie complet des données en santé, from 2021-04-01 to 2022-08-31
Recently finished projects
- Utilisation de l'intelligence artificielle (IA) afin de prédire les résultats de biopsies faites pour les mammographies anormales avec comme but ultime de réduire le nombre de biopsies , from 2019-12-09 to 2021-12-08